# | Title | Journal | Year | Citations |
---|
1 | Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans | Nature Medicine | 2004 | 538 |
2 | The Influence of Host and Bacterial Genotype on the Development of Disseminated Disease with Mycobacterium tuberculosis | PLoS Pathogens | 2008 | 410 |
3 | Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation | Nature Communications | 2013 | 256 |
4 | Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara | Proceedings of the National Academy of Sciences of the United States of America | 2005 | 228 |
5 | ChAd63-MVA–vectored Blood-stage Malaria Vaccines Targeting MSP1 and AMA1: Assessment of Efficacy Against Mosquito Bite Challenge in Humans | Molecular Therapy | 2012 | 196 |
6 | Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1 | Molecular Therapy | 2014 | 188 |
7 | Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors | PLoS ONE | 2012 | 157 |
8 | Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors | Molecular Therapy | 2011 | 156 |
9 | Manslaughter by Fake Artesunate in Asia—Will Africa Be Next? | PLoS Medicine | 2006 | 141 |
10 | Artemisinin resistance in Plasmodium falciparum is associated with an altered temporal pattern of transcription | BMC Genomics | 2011 | 135 |
11 | Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison | Lancet, The | 2006 | 133 |
12 | Taking social relationships seriously: Lessons learned from the informed consent practices of a vaccine trial on the Kenyan Coast | Social Science and Medicine | 2008 | 128 |
13 | Opa proteins and CEACAMs: pathways of immune engagement for pathogenicNeisseria | FEMS Microbiology Reviews | 2011 | 127 |
14 | Durable Human Memory T Cells Quantifiable by Cultured Enzyme-Linked Immunospot Assays Are Induced by Heterologous Prime Boost Immunization and Correlate with Protection against Malaria | Journal of Immunology | 2005 | 123 |
15 | Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials | Tuberculosis | 2005 | 114 |
16 | Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age | Pediatric Infectious Disease Journal | 2010 | 114 |
17 | Fatal Plasmodium falciparum Malaria Causes Specific Patterns of Splenic Architectural Disorganization | Infection and Immunity | 2005 | 111 |
18 | Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study | BMJ: British Medical Journal | 2008 | 108 |
19 | Safety and Immunogenicity of a New Tuberculosis Vaccine, MVA85A, in Mycobacterium tuberculosis–infected Individuals | American Journal of Respiratory and Critical Care Medicine | 2009 | 107 |
20 | Prime-boost immunisation strategies for tuberculosis | Microbes and Infection | 2005 | 103 |
21 | The Magnitude of the Antibody and Memory B Cell Responses during Priming with a Protein-Polysaccharide Conjugate Vaccine in Human Infants Is Associated with the Persistence of Antibody and the Intensity of Booster Response | Journal of Immunology | 2008 | 101 |
22 | Synergistic DNA–MVA prime-boost vaccination regimes for malaria and tuberculosis | Vaccine | 2006 | 97 |
23 | Boosting with Poxviruses Enhances Mycobacterium bovis BCG Efficacy against Tuberculosis in Guinea Pigs | Infection and Immunity | 2005 | 95 |
24 | Prime-boost strategies for malaria vaccine development | Journal of Experimental Biology | 2003 | 89 |
25 | Antibody Persistence after Serogroup C Meningococcal Conjugate Immunization of United Kingdom Primary‐School Children in 1999–2000 and Response to a Booster: A Phase 4 Clinical Trial | Clinical Infectious Diseases | 2010 | 83 |
26 | Clinical and Microbiological Features of HIV-Associated Tuberculous Meningitis in Vietnamese Adults | PLoS ONE | 2008 | 82 |
27 | Correlation of Memory T Cell Responses against TRAP with Protection from Clinical Malaria, and CD4+ CD25high T Cells with Susceptibility in Kenyans | PLoS ONE | 2008 | 82 |
28 | Transmission-Blocking Activities of Quinine, Primaquine, and Artesunate | Antimicrobial Agents and Chemotherapy | 2006 | 80 |
29 | Immune Inhibitory Ligand CD200 Induction by TLRs and NLRs Limits Macrophage Activation to Protect the Host from Meningococcal Septicemia | Cell Host and Microbe | 2010 | 80 |
30 | Genetic diversity of Plasmodium vivax in Kolkata, India | Malaria Journal | 2006 | 74 |
31 | Safety and Tolerability of Conserved Region Vaccines Vectored by Plasmid DNA, Simian Adenovirus and Modified Vaccinia Virus Ankara Administered to Human Immunodeficiency Virus Type 1-Uninfected Adults in a Randomized, Single-Blind Phase I Trial | PLoS ONE | 2014 | 72 |
32 | Sensitivity of IFN-γ Release Assay to Detect Latent Tuberculosis Infection Is Retained in HIV-Infected Patients but Dependent on HIV/AIDS Progression | PLoS ONE | 2008 | 69 |
33 | Poor quality drugs: grand challenges in high throughput detection, countrywide sampling, and forensics in developing countries | Analyst, The | 2011 | 69 |
34 | Destabilisation and subsequent lysis of human erythrocytes induced by Plasmodium falciparum haem products | European Journal of Haematology | 2005 | 68 |
35 | Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial | Molecular Therapy | 2014 | 68 |
36 | The relationship between human effector and memory T cells measured by ex vivo and cultured ELISPOT following recent and distal priming | Immunology | 2009 | 67 |
37 | Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers | Vaccine | 2006 | 65 |
38 | Assessment of Humoral Immune Responses to Blood-Stage Malaria Antigens following ChAd63-MVA Immunization, Controlled Human Malaria Infection and Natural Exposure | PLoS ONE | 2014 | 65 |
39 | Safety and Immunogenicity of Heterologous Prime-Boost Immunisation with Plasmodium falciparum Malaria Candidate Vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in Healthy Gambian and Kenyan Adults | PLoS ONE | 2013 | 64 |
40 | Immunogenicity and Safety of a Combination Pneumococcal-Meningococcal Vaccine in Infants | JAMA - Journal of the American Medical Association | 2005 | 63 |
41 | Limited Polymorphism in the Dihydropteroate Synthetase Gene ( dhps ) of Plasmodium vivax Isolates from Thailand | Antimicrobial Agents and Chemotherapy | 2005 | 63 |
42 | Impaired IFN-γ-secreting capacity in mycobacterial antigen-specific CD4 T cells during chronic HIV-1 infection despite long-term HAART | Aids | 2006 | 63 |
43 | Effect of needle size on immunogenicity and reactogenicity of vaccines in infants: randomised controlled trial | BMJ: British Medical Journal | 2006 | 62 |
44 | Quadrivalent meningococcal conjugate vaccines | Vaccine | 2009 | 61 |
45 | Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A | PLoS ONE | 2009 | 61 |
46 | Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines | Archives of Disease in Childhood | 2007 | 57 |
47 | Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials | PLoS ONE | 2007 | 57 |
48 | Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design | Lancet Infectious Diseases, The | 2006 | 55 |
49 | Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants | Molecular Therapy | 2016 | 52 |
50 | Micronutrient status in lactating mothers before and after introduction of fortified flour: cross-sectional surveys in Maela refugee camp | European Journal of Nutrition | 2012 | 51 |